锦好医疗(872925) - 2022 Q4 - 年度业绩预告

Financial Performance - The net profit attributable to shareholders for 2022 is expected to be 40.30 million CNY, representing a 76.11% increase compared to 22.88 million CNY in the previous year[3] - The company experienced an increase in foreign exchange gains due to the appreciation of the US dollar, which positively impacted the gross profit margin and net profit[5] Revenue Composition - Hearing aid products accounted for over 90% of total revenue, with a significant increase in the sales of high-margin digital hearing aids contributing to the overall profit margin[4] Cautionary Notes - The financial data presented is preliminary and has not been audited, and investors are advised to exercise caution[6]